We are focused on discovering and licensing novel molecular biomarkers for non-invasive diagnostic applications.
Founded in 2025, Double-Strand LLC primary mission is to determine, with high confidence, which molecular elements (e.g., germline variations or steady-state levels of RNA molecules) contribute to, or are associated with, specific endpoints of interest. Our team is dedicated to uncovering the potential of circulating nucleic acids to detect diseases earlier and improve patient outcomes.
Our mission is to discover and develop molecular diagnostics in oncology to provide patients and clinicians with timely, accurate insights. By licensing our cutting-edge biomarkers, we aim to accelerate the development of tests that save lives.